

November 12, 2024

The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sir

Subject: **Outcome of Board Meeting.**

This has reference to our letter dated 03rd November 2024.

At the meeting of Board of Directors of the company held on Tuesday 12th November 2024, the following decisions were taken:

1. Un-Audited Financial Results (standalone and consolidated) for the quarter and half year ended 30.09.2024. (Attached).
2. Limited Review Report (standalone and consolidated) for the Quarter and half year ended 30.09.2024. (Attached).
3. The Board considered and approved the Notice of the 34th Annual General meeting for the Financial Year 2023-2024 and other related matters thereto.
4. The Board considered and approved Directors' Report and the annexure thereon for the Financial Year 2023-2024.
5. It was decided to hold the 34th Annual General Meeting on Thursday the 05th December 2024 at IST through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") at 10.00 A.M. (IST).
6. The Register of Members and Share Transfer Books of the Company will remain closed from Friday the 29th November 2024 to Thursday the 05th December, 2024 (both days inclusive).
7. Appointment of Mrs. Geeta Sherwani, Company Secretary as the Scrutinizer for e voting.

8. The e voting dates will be from 02-12-2024 at 10:00 am to 04-12-2024 up to 5:00pm.
9. Re-appointment of Mrs. Swetha Marri as an Independent Director of the company.
10. SAT hearing is due to be heard on 28th November 2024.
11. Legal Notice from BIRAC intimating about potential Arbitration/CIRP proceedings against the company if the company fails to pay an amount of Rs. 7,57,81,871.23 that includes Rs. 3,87,00,000 towards the principal amount while the rest as interest. The management plans to clear these dues at the earliest.
12. A notice from the Commissioner of Customs has been received for a payment of Rs.25,24,803. Appropriate legal steps have been initiated for a resolution on this matter.
13. Mr. Nitin Didwania's long pending legal claim is to be heard on 18th November 2024 by the Hon'ble HC at Bombay.

The meeting commenced at 11.00 A.M and concluded at 12.00 Noon.

This is for your information and records.

Thanking you

Yours Sincerely

For **TRANSGENE BIOTEK LIMITED**



DR K KOTESWARA RAO

MANAGING DIRECTOR

DIN NO: 02287235

Encls: as above



M/S VASAVI & CO

Chartered Accountants

Limited Review report

To
The Board of Directors,
M/s TRANSGENE BIOTEK LIMITED
Hyderabad

We have reviewed the accompanying statement of unaudited standalone financial results of M/s TRANSGENE BIOTEK LIMITED for the Quarter ended 30th September 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASAVI & CO,
Chartered Accountants
FRN 020965S

G.R.L. Vasavi

(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259



UDIN for this document is: 24249259BKHJ005489

Place: Hyderabad

Date: 12/11/2024



M/S VASAVI & CO

Chartered Accountants

Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
M/s Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s Transgene Biotek Ltd ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates for the quarter ended 30/09/2024 being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30/09/2024 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the following entities:

1. Transgene Biotek HK Ltd - Subsidiary

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial results of subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 September 2024, as considered in the consolidated unaudited financial results.

**For VASAVI & CO,
Chartered Accountants
FRN 020965S**

G.R.L. Vasavi

**(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259**



UDIN for this document is: 24249259BKHJ005489

**Place: Hyderabad
Date: 12/11/2024**



TRANSGENE
BIOTEK LIMITED

TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

(In Lakhs)

Standalone Statement of assets and liabilities

PARTICULARS	As at 30 September 2024	As at 31 March 2024
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	162.86	167.14
(b) Right of Use Assets	-	-
(c) Capital work-in-progress	-	-
(d) Investment Properties	-	-
(e) Goodwill	-	-
(f) Other intangible assets	468.11	468.47
(g) Intangible assets under development	186.77	186.77
(h) Biological Assets Other Than Bearer Plants	-	-
(i) Financial assets	-	-
(i) Investments	9.50	9.50
(ii) Trade Receivables	-	-
(iii) Loans	2302.04	2302.04
(iv) Other Financial Assets	-	-
(j) Deferred Tax Assets (Net)	-	-
(k) Other non-current assets	-	-
SUB-TOTAL	3129.28	3133.92
CURRENT ASSETS		
(a) Inventories	3.40	3.39
(b) Financial assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iii) Cash and cash equivalents	1.12	0.76
(iv) Bank Balances other than (iii) above	0.01	0.01
(v) Loans	-	-
(vi) Other Financial Assets	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	83.70	105.95
SUB-TOTAL	88.23	110.11
Non-Current Assets Classified as Held for Sale	-	-
TOTAL ASSETS	3217.50	3244.03

EQUITY AND LIABILITIES	As at 30 September 2024	As at 31 March 2024
EQUITY		
Equity share capital	7577.00	7577.00
Other equity	-8251.49	-8264.09
SUB-TOTAL	-674.49	-687.09
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	496.40	507.95
(ii) Trade Payable	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	2302.04	2302.04
(c) Deferred tax liabilities (net)	0.00	0.00
(d) Other non-current liabilities	8.77	17.54
SUB-TOTAL	2807.22	2827.53
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	899.48	892.15
(ii) Trade payables	4.81	20.31
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	169.62	182.89
(c) Other current liabilities	10.87	8.23
(d) Current tax liabilities (net)	0.00	0.00
SUB-TOTAL	1084.78	1103.58
TOTAL EQUITY AND LIABILITIES	3217.50	3244.03
Corporate information and significant accounting policies		
The accompanying notes form an integral part of the Consolidated financial statements		

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 12-11-2024

Place:Hyderabad



TRANSGENE BIOTEK LIMITED

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2024

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Audited)	30.09.2024 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	5.85	4.92	4.50	10.77	23.49
2	Other income (net)	4.38	65.19	4.38	69.58	18.27
3	Total income (1 + 2)	10.23	70.12	8.88	80.35	41.76
4	EXPENSES					
	Cost of materials consumed	0.00	0.00	0.01	0.00	0.06
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	-	0.00	0.00
	Employee benefits expense	8.19	8.09	7.93	16.29	31.12
	Finance costs	1.73	1.73	3.23	3.45	12.91
	Depreciation and amortisation expense	2.32	2.32	2.31	4.65	9.23
	Other expenses	5.33	38.03	8.66	43.37	53.97
	Total expenses	17.57	50.18	22.14	67.75	107.30
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	-7.34	19.94	-13.26	12.60	-65.55
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00
7	Profit before tax (5 - 6)	-7.34	19.94	-13.26	12.60	-65.55
8	Tax expense					
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00
	Total tax expense	0.00	0.00	0.00	0.00	0.00
9	Profit for the year (7 - 8)	-7.34	19.94	-13.26	12.60	-65.55
10	Other comprehensive income					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the year (9 + 10)	-7.34	19.94	-13.26	12.60	-65.55
12	Earnings per equity share					
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.01)	0.03	(0.02)	0.02	(0.09)
	Diluted (Rs.)	(0.01)	0.03	(0.02)	0.02	(0.09)

Notes:

- 1 We are informed that the volunteers for the human clinical Studies on Oral Insulin are due to be recruited shortly. With the receipt of notices for payment from BIRAC, Cestat and others, the management is exploring possible avenues to raise
- 2 funds as a matter of urgency after receiving the shareholder approval at the next AGM due to be held shortly.
- 3 Final SAT hearing is scheduled for 28th November 2024
- 4 No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
- 5 The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors at their meeting held on 12th November 2024

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 12-11-2024

Place:Hyderabad

TRANSGENE BIOTEK LIMITED

68, 69 & 70, Anrich Industrial Area, Bollarum, MEDAK DISTRICT.

Standalone Statement of Cash Flows for the year ended 30th September 2024

(In Lakhs)

Particulars	For the year ended September 30, 2024		For the year ended March 31, 2024	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		12.60		-65.55
<u>Adjustments for :</u>				
Depreciation and amortisation expense	4.65		9.23	
Finance costs	3.45		12.91	
Amortisation of government grant	-8.77		-17.54	
Supplier Advances Written off	-15.00			
Bad debts written off				
Profit or loss on sale of Fixed asset				
Other Non cash Expenses				
Operating profit before working capital changes		-3.07		-60.94
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables				
Other non-current assets				
Other Current assets	22.24		-6.00	
Inventories	-0.01		-0.01	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	-15.50		-2.56	
Provision (CL)	-13.28		0.83	
Borrowing (CL)	7.33		75.21	
Other financial liabilities				
Other current liabilities	2.64		-6.05	
Provison (NCL)				
Cash generated from operations		0.36		0.46
Net income tax paid				
Net cash flow from operating activities (A)		0.36		0.46
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances				
Investments				
Proceeds from sale of fixed assets				
Net cash (used in) / flow from investing activities (B)		0.00		0.00
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares				
Finance costs				
Proceeds from Borrowings				
Payment of Borrowing				
Net cash flow (used in) financing activities (C)		0.00		0.00
Net (decrease) in Cash and cash equivalents (A+B+C)		0.36		0.46
Cash and cash equivalents at the beginning of the year		0.77		0.31
Effect of exchange differences on translation of foreign currency Cash and cash equivalents				
Cash and cash equivalents at the end of the year		1.13		0.77

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

TRANSGENE BIOTEK LIMITED

Notes forming part of the Standalone financial statements

Other expenses	(In Lakhs)
Particulars	For the Period ended September 30,2024
BSNL Fiber net	0.04
Conveyance Expenses	0.43
Directors sitting fee	0.15
Legal and Professional Charges	3.95
Miscllaneous Expenses	0.02
Postage and Courier Expenses	0.06
Printing and Stationary	0.02
Rates, taxes and duties	0.04
SEBI Expenses	0.10
Telephone Expenses	0.02
Travelling Expenses	0.06
Insurance	0.14
Website and Software	0.16
Advertisement	0.13
Business promotional exp	0.03
Interest and penalties	0.00
Bank charges	0.00
Total	5.33

For TRANSGENE BIOTEK LIMITED

**Dr.K.Koteswara Rao**
Managing Director

Date: 12-11-2024

Place:Hyderabad

**TRANSGENE BIOTEK LIMITED**

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

(In Lakhs)

Consolidated Statement of assets and liabilities

PARTICULARS	As at 30 September 2024	As at 31 March 2024
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	162.86	167.14
(b) Right of Use Assets	-	-
(c) Capital work-in-progress	-	-
(d) Investment Properties	-	-
(e) Goodwill	-	-
(f) Other intangible assets	468.11	468.47
(g) Intangible assets under development	186.77	186.77
(h) Biological Assets Other Than Bearer Plants	-	-
(i) Financial assets	-	-
(i) Investments	9.50	9.50
(ii) Trade Receivables	-	-
(iii) Loans	13290.24	13290.24
(iv) Other Financial Assets	-	-
(j) Deferred Tax Assets (Net)	-	-
(k) Other non-current assets	-	-
SUB-TOTAL	14117.47	14122.12
CURRENT ASSETS		
(a) Inventories	3.40	3.39
(b) Financial assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	84,460.00	84,460.00
(iii) Cash and cash equivalents	1.12	0.76
(iv) Bank Balances other than (iii) above	0.01	0.01
(v) Loans	-	-
(vi) Other Financial Assets	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	83.70	105.95
SUB-TOTAL	89.07	110.95
Non-Current Assets Classified as Held for Sale	-	-
TOTAL ASSETS	14206.55	14233.07

EQUITY AND LIABILITIES	As at 30 September 2024	As at 31 March 2024
EQUITY		
Equity share capital	7577.00	7577.00
Other equity	-6493.81	-6505.67
SUB-TOTAL	1083.19	1071.33
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	496.40	507.95
(ii) Trade Payable	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	11522.14	11522.14
(c) Deferred tax liabilities (net)	0.00	0.00
(d) Other non-current liabilities	8.77	17.54
SUB-TOTAL	12027.31	12047.63
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	899.48	892.15
(ii) Trade payables	4.81	19.57
(iii) Other financial liabilities	11.26	11.26
(b) Provisions	169.62	182.89
(c) Other current liabilities	10.87	8.23
(d) Current tax liabilities (net)	0.00	0.00
SUB-TOTAL	1096.04	1114.11
TOTAL EQUITY AND LIABILITIES	14206.55	14233.07
Corporate information and significant accounting policies		
The accompanying notes form an integral part of the Consolidated financial statements		

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 12-11-2024

Place:Hyderabad



TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2024

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year Ended
		30.06.2024 (Unaudited)	31.03.2024 (Unaudited)	30.06.2023 (Unaudited)	30.06.2024 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	5.85	4.92	4.50	10.77	23.49
2	Other income (net)	4.38	65.19	4.38	69.58	18.27
3	Total income (1 + 2)	10.23	70.12	8.88	80.35	41.76
4	EXPENSES					
	Cost of materials consumed	0.00	0.00	0.01	0.00	0.06
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	-	0.00	0.00
	Employee benefits expense	8.19	8.09	7.93	16.29	31.12
	Finance costs	1.73	1.73	3.23	3.45	12.91
	Depreciation and amortisation expense	2.32	2.32	2.31	4.65	9.23
	Other expenses	5.33	38.03	8.66	43.37	53.97
	Total expenses	17.57	50.18	22.14	67.75	107.30
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	-7.34	19.94	-13.26	12.60	-65.55
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00
7	Profit before tax (5 - 6)	-7.34	19.94	-13.26	12.60	-65.55
8	Tax expense					
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00
	Total tax expense	0.00	0.00	0.00	0.00	0.00
9	Profit for the year (7 - 8)	-7.34	19.94	-13.26	12.60	-65.55
10	Other comprehensive income					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the year (9 + 10)	-7.34	19.94	-13.26	12.60	-65.55
12	Earnings per equity share					
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.01)	0.03	(0.02)	0.02	(0.09)
	Diluted (Rs.)	(0.01)	0.03	(0.02)	0.02	(0.09)

Notes:

- 1 We are informed that the volunteers for the human clinical Studies on Oral Insulin are due to be recruited shortly.
- 2 With the receipt of notices for payment from BIRAC, Cestat and others, the management is exploring possible avenues to raise funds as a matter of urgency after receiving the shareholder approval at the next AGM due to be held shortly.
- 3 Final SAT hearing is scheduled for 28th November 2024
- 4 No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
- 5 The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors at their meeting held on 12th November 2024.

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 12-11-2024
Place:Hyderabad

TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollaram, SAGAREDDY DISTRICT.

Consolidated Statement of Cash Flows for the year ended 30th September 2024

(In Lakhs)

Particulars	For the year ended September 30, 2024		For the year ended March 31, 2024	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		12.60		-65.55
<i>Adjustments for :</i>				
Depreciation and amortisation expense	4.65		9.23	
Finance costs	3.45		12.91	
Amortisation of government grant	-8.77		-17.54	
Supplier Advances Written off	-15.00			
Bad debts written off				
Profit or loss on sale of Fixed asset				
Other Non cash Expenses				
Operating profit before working capital changes		-3.07		-60.94
<i>Changes in working capital:</i>				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Trade receivables				
Other non-current assets				
Other Current assets	22.24		-6.00	
Inventories	-0.01		-0.01	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
Trade payables	-14.76		-2.56	
Provision (CL)	-13.28		0.83	
Borrowing (CL)	7.33		75.21	
Other financial liabilities				
Other current liabilities	2.64		-6.05	
Provison (NCL)				
Cash generated from operations		1.09		0.46
Net income tax paid				
Net cash flow from operating activities (A)		1.09		0.46
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances				
Investments				
Proceeds from sale of fixed assets				
Net cash (used in) / flow from investing activities (B)		0.00		0.00
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares				
Finance costs				
Proceeds from Borrowings				
Payment of Borrowing				
Net cash flow (used in) financing activities (C)		0.00		0.00
Net (decrease) in Cash and cash equivalents (A+B+C)		1.09		0.46
Cash and cash equivalents at the beginning of the year		0.77		0.31
Effect of exchange differences on translation of foreign currency Cash and cash equivalents				
Cash and cash equivalents at the end of the year		1.86		0.77

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 12-11-2024

Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Notes forming part of the Consolidated financial statements

Other expenses	(In Lakhs)
Particulars	For the Period ended September 30,2024
BSNL Fiber net	0.04
Conveyance Expenses	0.43
Directors sitting fee	0.15
Legal and Professional Charges	3.95
Miscllaneous Expenses	0.02
Postage and Courier Expenses	0.06
Printing and Stationary	0.02
Rates, taxes and duties	0.04
SEBI Expenses	0.10
Telephone Expenses	0.02
Travelling Expenses	0.06
Insurance	0.14
Website and Software	0.16
Advertisement	0.13
Business promotional exp	0.03
Interest and penalties	0.00
Bank charges	0.00
Total	5.33

For TRANSGENE BIOTEK LIMITED

**Dr.K.Koteswara Rao**
Managing Director

Date:12-11-2024

Place:Hyderabad